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Background: Direct-acting antivirals are successful in curing hepatitis C virus infection in more than 95% of patients treated for 12
weeks, but theyareexpensive.Shortened treatmentdurations,whichmayhave lowercure rates, havebeenproposed toreducecosts.
Objectives: To evaluate the lifetime cost-effectiveness of different shortened treatment durations for genotype 1 noncirrhotic
treatment-naive patients.
Methods: Assuming a UK National Health Service perspective, we used a probabilistic decision tree and Markov model to
compare 3 unstratified shortened treatment durations (8, 6, and 4 weeks) against a standard 12-week treatment duration.
Patients failing shortened first-line treatment were re-treated with a 12-week treatment regimen. Parameter inputs were
taken from published studies.
Results: The 8-week treatment duration had an expected incremental net monetary benefit of £7737 (95% confidence interval
£3242-£11819) versus the standard 12-week treatment, per 1000 patients. The 6-week treatment had a positive incremental
net monetary benefit, although some uncertainty was observed. The probability that the 8- and 6-week treatments were the
most cost-effective was 56% and 25%, respectively, whereas that for the 4-week treatment was 17%. Results were generally
robust to sensitivity analyses, including a threshold analysis that showed that the 8-week treatment was the most cost-
effective at all drug prices lower than £40 000 per 12-week course.
Conclusions: Shortening treatments licensed for 12 weeks to 8 weeks is cost-effective in genotype 1 noncirrhotic treatment-
naive patients. There was considerable uncertainty in the estimates for 6- and 4-week treatments, with some indication that
the 6-week treatment may be cost-effective.
Keywords: cost-effectiveness, direct-acting antivirals, hepatitis C virus, shortened treatment duration.
VALUE HEALTH. 2019; 22(6):693–703Nevertheless, the cost of a standard 12-week treatment course isIntroduction
The cost-effectiveness of direct-acting antiviral (DAA) treat-
ment for chronic hepatitis C virus (HCV) has been well
documented,1-4 and a wide array of DAA therapies have been
approved for use internationally.5 The therapies, which are
generally administered orally over 12 weeks, are successful in
more than 95% of patients with chronic HCV genotype 1 (GT1).5
The advent of an effective cure has brought the potential to
address HCV globally. The World Health Organization recently
outlined its commitment toward eliminating HCV by 2030.6Barnes, PhD, Jonathan Ball, PhD, Diana Brainard, MD, Gary Burgess, Graham
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doi.org/10.1016/j.jval.2018.12.011high, and variations in price exist internationally and across DAA
regimens. In the United Kingdom, the price set by manufacturers
initially ranged from £30 000 to £60 000 per patient,7-9 whereas in
the United States, a 12-week course of treatment can cost more
than $90 000 per patient.10 Although significantly lower prices
have been agreed between manufacturers and healthcare payers,
these prices have not been made publicly available. Shortened
treatment duration is a mechanism that could be used to reduce
drug costs, albeit at the expense of potentially curing fewer
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694 VALUE IN HEALTH JUNE 2019Recent evidence suggests that shortened treatment durations
are associated with lower cure rates in GT1 noncirrhotic
treatment-naive patients. Kowdley et al11 reported that the cure
rate fell from 96% in patients treated for 12 weeks using a triple-
DAA regimen (ombitasvir-paritaprevir-ritonavir with dasabuvir
[3D]) to 88% in patients treated for 8 weeks with the same
regimen. Sulkowski et al12 considered shorter treatment durations
using a combination of 4 DAAs (daclatasvir, asunaprevir, becla-
buvir, and sofosbuvir [DCV-Trio 1 SOF]) and found that 57% and
29% of patients treated over 6 and 4 weeks, respectively, cleared
the virus. Other studies considered the effectiveness of existing
DAA therapies over shortened treatment durations, but with the
addition of an investigational nonnucleoside or protease inhibitor.
For example, Kohli et al13 found that 40% of patients were cured
when treated for 4 weeks using ledipasvir and sofosbuvir
(LDV/SOF) plus a nonnucleoside inhibitor (GS9669).
Although cure rates are lower over shortened treatment
durations, patients can usually be re-treated with an alternative,
or similar, DAA regimen if first-line treatment fails. One concern
with first-line treatment failure, however, is that patients can
develop resistance to DAA therapies and this can affect the
likelihood of future viral eradication.14 Nevertheless, much
evidence suggests that noncirrhotic patients with DAA resistance,
or resistance-associated polymorphisms, can clear the virus with
further treatment15-19 even before the advent of combinations
with broader antiviral activity. Wilson et al19 found that 90% of
patients with DAA resistance were cured with a 12-week
re-treatment using LDV/SOF, whereas 91% of patients overall
were cured after shortened first-line treatment failure. Bourliere
et al20 found that 97% of patients who previously failed first-line
treatment cleared the virus over 12 weeks using sofosbuvir/
velpatasvir/voxilaprevir (SOF/VEL/VOX).
Given the burden of high treatment costs, and the potential to
cure as many patients using shortened treatment durations
(with a re-treatment strategy adopted for all patients who fail
first-line treatment), the cost-effectiveness of short-course
therapy needs to be considered. In this article, we compared
the lifetime cost-effectiveness of different unstratified shortened
treatment durations. We modeled outcomes for GT1 noncirrhotic
treatment-naive patients with HCV in the United Kingdom, for
whom shortened treatment has been reported in the literature,
and for whom shortened treatment may be considered in the
future.Methods
We used a decision tree and Markov model to investigate the
cost-effectiveness of shortened DAA treatment from the National
Health Service perspective in the United Kingdom. We applied
monthly cycles during the first year in the decision tree to
simulate treatment outcomes and annual cycles in the Markov
model to simulate the natural history of HCV. We adopted a
lifetime time horizon (60 years, from an initial age of 40 years) and
discounted costs and utilities at 3.5% per annum, as per the
National Institute for Health and Care Excellence (NICE)
guidelines.21
Target Population
The model simulated outcomes for GT1 noncirrhotic
treatment-naive patients infected with HCV, combining data from
subtypes 1a and 1b. We modeled outcomes for a representative
population with noncirrhotic HCV in the United Kingdom, on the
basis of Hartwell et al.22 At baseline, 51.1% and 48.9% of patientshad mild (F0-F1) and moderate (F2-F3) liver fibrosis, respectively.
At model entry, patients were aged 40 years and 70% were men
(Table 1).
Treatment Comparators and Regimens
We compared 3 unstratified shortened treatment durations
(8, 6, and 4 weeks) against the standard 12-week treatment
duration. We considered treatment regimens currently used in the
United Kingdom in our analysis. In the base-case analysis, we used
a triple-DAA regimen (3D) for first-line treatment because of the
availability of data on the effectiveness of shortened treatment.11
3D contains 2 fixed-dose tablets with 12.5 mg ombitasvir, 75 mg
paritaprevir, and 50 mg ritonavir, which are taken daily along with
1 dose of 250 mg dasabuvir.8
We assumed that patients who failed first-line treatment were
re-treated for 12 weeks, as per recent UK guidelines.30,31 We used
SOF/VEL/VOX as the salvage regimen. SOF/VEL/VOX is a
nonstructural protein 5A (NS5A) inhibitor-containing regimen
that is administered once daily using a fixed-dose tablet; each
tablet contains 400 mg sofosbuvir, 100 mg velpatasvir (NS5A
inhibitor), and 100 mg voxilaprevir (protease inhibitor).28
SOF/VEL/VOX is the currently recommended treatment regimen
for patients who previously failed first-line treatment in the
United Kingdom.30,31
Model Structure
The decision tree was designed to capture treatment outcomes
in the first year using monthly cycles (Figure 1A). Patients were
assessed for sustained virological response at 12 weeks
posttreatment (SVR12, effective cure), which was defined as
having HCV ribonucleic acid less than 25 IU per milliliter. Patients
who failed first-line treatment were re-treated at 24 weeks. All
patients entered the Markov model on the basis of their response
to treatment.
The Markov model was adapted from previously validated
models that characterize the natural disease history of
HCV.3,22,32,33 Patients entered the model on the basis of their
initial distribution of liver fibrosis (mild or moderate), and
whether treatment had been successful (Figure 1B). In HCV-
cleared patients, we modeled potential reinfection. Patients
without SVR12 could progress from mild (F0-F1) to moderate (F2-
F3) to severe liver fibrosis, or compensated cirrhosis (F4). Once in
this health state, patients could develop more advanced liver
disease, including hepatocellular carcinoma and decompensated
cirrhosis. Patients with decompensated cirrhosis were also at risk
of hepatocellular carcinoma, with both groups of patients at risk of
requiring a liver transplant. We modeled liver-related deaths for
each of these advanced health states with 2 health states captured
in the hepatocellular carcinoma and liver transplant health
states to reflect the initial and subsequent risk of liver-related
mortality. At any stage in the Markov model, patients could die
of non–liver-related deaths.
Model Assumptions
We assumed there was no progression to more severe health
states during treatment, such as compensated cirrhosis (F4), or
once treatment had been successful. Only if patients became
reinfected could disease progression occur. There are no clinical
guidelines on the appropriate length of time patients should wait
before a salvage treatment is administered. In our model, we
assumed that the wait time did not affect the success of
re-treatment.
Table 1. Summary of treatment, epidemiological, cost, and quality-of-life inputs for probabilistic sensitivity analyses.
Variable Base case Distribution a b Source
Patient characteristics
Initial distribution of liver fibrosis
Mild (F0-F1) 51.1% – – – Hartwell et al22
Moderate (F2-F3) 48.9% – – – Hartwell et al22
Age (y) 40 – – – Hartwell et al22
Sex, male 70% – – – Hartwell et al22
Efficacy (SVR12)
First-line treatment
12 wk 0.96 Beta 76 3 Kowdley et al11
8 wk 0.87 Beta 69 10 Kowdley et al11
6 wk 0.64 Beta 6 3 Sulkowski et al12,*
4 wk 0.38 Beta 1 2 Sulkowski et al12,*
Re-treatment
12 wk 0.973 Beta 142 4 Bourliere et al20
Annual transition probabilities
Fibrosis progression
Mild-to-moderate 0.025 Beta 38 1484 Grieve et al,23 Wright et al24
Moderate-to-CC 0.037 Beta 27 699 Grieve et al,23 Wright et al24
Nonfibrosis progression
CC-to-DCC 0.039 Beta 15 359 Fattovich et al25
CC-to-HCC 0.014 Beta 2 135 Cardoso et al26
DCC-to-HCC 0.014 Beta 2 135 Cardoso et al26
HCC-to-liver transplant 0.020 Beta 98 4801 Hartwell et al22
DCC-to-liver transplant 0.020 Beta 98 4801 Grieve et al23
Liver-related mortality
DCC-to-liver death 0.130 Beta 147 983 Fattovich et al25
HCC-to-liver death (first year) 0.430 Beta 117 155 Fattovich et al25
HCC-to-liver death (subsequent year) 0.430 Beta 117 155 Fattovich et al25
Liver transplant-to-liver death (first year) 0.150 Beta 85 481 Grieve et al23
Liver transplant-to-liver death (subsequent year) 0.057 Beta 85 1407 Bennett et al27
Reinfection 0.010 Beta 4 391 Johnson et al3
Costs
Treatment-related costs
3D (monthly) £12 140.56 Fixed – – National Institute for Health
and Care Excellence8
SOF/VEL/VOX (monthly) £14 942.33 Fixed – – National Institute for Health
and Care Excellence28
Monitoring costs (monthly) £162.34 Fixed – – National Institute for Health
and Care Excellence8
Health state costs
SVR mild (F0-F1) £60.36 Gamma 34 2 Backx et al29
SVR moderate (F2-F3) £60.36 Gamma 34 2 Backx et al29
Mild (F0-F1) £166.50 Gamma 13 13 Hartwell et al22
Moderate (F2-F3) £612.50 Gamma 35 17 Backx et al29
CC (F4) £951.13 Gamma 17 54 Backx et al29
DCC £12 833.96 Gamma 15 849 Hartwell et al22
HCC (first year) £11 436.41 Gamma 13 894 Hartwell et al22
HCC (subsequent year) £11 436.41 Gamma 13 894 Hartwell et al22
Liver transplant (first year) £51 769.79 Gamma 15 3473 Hartwell et al22
Liver transplant (subsequent year) £1949.08 Gamma 14 136 Hartwell et al22
Adverse event costs
Anemia £501.58 Gamma 10 48 Johnson et al3
Rash £166.50 Gamma 16 10 Johnson et al3
Depression £414.17 Gamma 16 26 Johnson et al3
Neutropenia £980.26 Gamma 10 98 Johnson et al3
Thrombocytopenia £875.16 Gamma 14 62 Johnson et al3
Utilities
Treatment-related utilities (penalties)
Mild (F0-F1)—3D (monthly) 20.001 Fixed – – Johnson et al3
Moderate (F2-F3)—3D (monthly) 20.001 Fixed – – Johnson et al3
Health state utilities
SVR mild (F0-F1) 0.820 Fixed – – Wright et al24
SVR moderate (F2-F3) 0.710 Fixed – – Wright et al24
Mild (F0-F1) 0.770 Beta 141 42 Wright et al24
Moderate (F2-F3) 0.660 Log-normal – – Wright et al24
CC (F4) 0.550 Log-normal – – Wright et al24
continued on next page
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Table 1. Continued
Variable Base case Distribution a b Source
DCC 0.450 Beta 55 67 Wright et al24
HCC (first year) 0.450 Beta 55 67 Wright et al24
HCC (subsequent year) 0.450 Beta 55 67 Wright et al24
Liver transplant (first year) 0.450 Beta 55 67 Hartwell et al22
Liver transplant (subsequent year) 0.670 Beta 32 16 Wright et al24
CC indicates compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir; SVR12, sustained
virological response at 12 wk; 3D, ombitasvir, paritaprevir, ritonavir with dasabuvir.
*Synthesized from Kowdley et al11 and Sulkowski et al12 (for further details, see Appendix 1 in Supplemental Materials found at https://doi.org/10.1016/j.jval.2018.12.011).
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We informed the model using a synthesis of evidence, as
presented in Table 1 and described herein.
Treatment-related inputs
We synthesized evidence from 2 sources to inform the efficacy
of first-line 3D treatment. Kowdley et al11 reported SVR12 for 3D
after 12 and 8 weeks of treatment, on the basis of a large phase 2b
clinical trial with 571 patients, and found that 96% and 88% of
patients, respectively, cleared the virus. Evidence on shorter
treatment durations for 3D was not available; nevertheless, SVR12
for an alternative DAA regimen using DCV-Trio 1 SOF was re-
ported by Sulkowski et al12 for a similar population after 6 and 4
weeks of treatment. The small phase 2 clinical trial with 28 pa-
tients reported that 57% and 29% of patients achieved SVR12 after
6 and 4 weeks of treatment, respectively. For our analysis, we
assumed that the odds ratio of SVR12 after 6 and 4 weeks of
treatment using DCV-Trio 1 SOF could be applied to 3D. We
calculated the odds ratio of available data (ie, 8 vs 12 weeks and 4
vs 6 weeks), averaged these to estimate 8 versus 6 weeks, and
applied these to our baseline 3D estimates to obtain predicted
estimates for 6 and 4 weeks for 3D therapy. We used a Bayesian
Markov chain Monte-Carlo simulation framework to pool the
evidence to propagate and reflect the uncertainties in these
estimates for use in probabilistic sensitivity analysis (for further
details, see Appendix 1 in Supplemental Materials found at
10.1016/j.jval.2018.12.011). The estimated SVR12 was 96%, 87%,
64%, and 38% after 12, 8, 6, and 4 weeks of treatment, respectively,
with uncertainty around these estimates presented in Table 1.
Bourliere et al20 provided evidence on the efficacy of
re-treatment using SOF/VEL/VOX from 2 phase 3 clinical trials
(POLARIS-1 and POLARIS-4). Overall, 97.3% of patients achieved
SVR12; we used this parameter to inform the expected SVR12 in
patients who failed any of the treatment strategies. We assessed
uncertainty in this parameter using data obtained from Bourliere
et al20 and beta distributions.
Treatment-related adverse events associated with DAA treat-
ment were modeled to reflect the potential impact of these clinical
events over different treatment durations. We obtained the
probability of adverse events occurring from a clinical trial of 3D
treatment, as reported by Johnson et al.3 To estimate the
probability of these events occurring over different treatment
durations, we converted the probabilities to rates and calculated
the time-dependent probability for each strategy (see Appendix 2
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
018.12.011). We assumed that the probability of adverse events
occurring was the same for re-treatment as for first-line treat-
ment. The adverse events included anemia, rash, depression,
grade 3 or 4 neutropenia, and grade 3 or 4 thrombocytopenia.Epidemiological inputs
The Markov model simulated the natural disease history of
HCV using annual transition probabilities, which are presented in
Table 1. We derived estimates from published studies on the
probability of reinfection (1% per annum),3 fibrosis23,24 and
nonfibrosis25,26 progression, liver-related mortality,23,25,27 and
all-cause mortality, stratified by age and sex.34
Costs
The model considered both treatment-related and health state
costs from the perspective of the National Health Service in the
United Kingdom (Table 1). All unit costs were expressed in sterling
(£) and valued at 2016/2017 prices.
The costs for the drug regimens were taken from the respective
NICE technology appraisals for 3D8 and SOF/VEL/VOX (Table 1).
These costs were applied on a pay-per-tablet basis, rather than a
pay-per-treatment success basis. We also considered monitoring
costs, and derived these from a previous technology appraisal for a
similar DAA.7 We assumed that monitoring costs were the same
for first-line treatment and re-treatment because these costs were
not expected to vary by DAA treatment. Treatment-related costs
(drug and monitoring costs) were assumed to be fixed in the
model because these prices were not expected to vary in the
United Kingdom. The costs associated with adverse events were
taken from the study by Johnson et al.3 We assessed uncertainty in
these estimates using gamma distributions.
Health state costs were derived from a previous UK evaluation
of HCV by Hartwell et al22 and a cost analysis of resource use
incurred by both HCV-infected and HCV-cleared patients,
undertaken by Backx et al.29 Gamma distributions were assumed
for all cost inputs. We updated costs to 2016/2017 prices using the
Hospital and Community Health Services index35 (Table 1).
Utility weights
We derived treatment-related and health state utility esti-
mates from published studies (Table 1). Johnson et al3 provided
treatment-related utilities for 3D treatment. The quality-of-life
estimates were obtained from the 5-level EuroQol 5-dimensional
questionnaire, which was administered to patients participating
in clinical trials for 3D treatment. For our analysis of shortened
treatment, we converted the 12-week treatment estimates to
reflect the monthly deterioration in quality of life because of
adverse events associated with treatment. We assumed the same
treatment-related utilities for SOF/VEL/VOX because these have
not yet been published.
Health state utilities for HCV infection were derived from
Wright et al24 and reflected the expected annual health-related
quality of life associated with each HCV health state. As in the
study by Wright et al,24 and other analyses,3,22 we assumed that
Figure 1. Economic model structure: (A) Decision tree simulating treatment outcomes; (B) Markov model simulating natural disease
history.
Markov model
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ECONOMIC EVALUATION 697the health utility associated with treatment success (SVR12) was
greater than the baseline utility level by a score of 0.05 for both
mild and moderate liver fibrosis. We assumed that the healthutility in successfully treated patients was fixed in the model. We
investigated uncertainty in infected patients using beta distribu-
tions (Table 1).
Table 2. Cost-effectiveness findings.
Analysis Costs (£) (95% CI) QALYs (95% CI) Cost per cure (£) (95% CI) INMB (£) (95% CI)*,y P(CE)y
Base-case analysis
12 wk 40911 (38 742 to 44 007) 15.51 (15.00 to 16.16) 41 051 (38788 to 44313) – .029
8 wk 32821 (29 513 to 36 971) 15.49 (14.98 to 16.14) 33 194 (29701 to 37669) 7 737 (3 242 to 11819) .558
6 wk 37668 (25 511 to 52 476) 15.44 (14.92 to 16.11) 39 048 (25746 to 56050) 1 860 (214 517 to 15153) .245
4 wk 43126 (20 506 to 59 551) 15.38 (14.83 to 16.07) 46 021 (20762 to 67835) 24735 (224197 to 20 141) .168
Sensitivity analysis (80% reduction in drug prices)
12 wk 11455 (9 951 to 13 657) 15.51 (14.99 to 16.16) 11 495 (9 972 to 13721) – .220
8 wk 9738 (8 083 to 12 016) 15.49 (14.97 to 16.14) 9 848 (8 136 to 12217) 1 370 (2344 to 2 685) .470
6 wk 10892 (7 617 to 14 835) 15.44 (14.90 to 16.11) 11290 (7 709 to 15949) 2815 (26868 to 3 170) .203
4 wk 12203 (6 634 to 17 020) 15.38 (14.82 to 16.07) 13 008 (6 706 to 19512) 23 197 (212090 to 4 291) .107
CI indicates confidence interval; INMB, incremental net monetary benefit; P(CE), probability most cost-effective; QALY, quality-adjusted life-year.
*Versus 12 wk.
yAt £20 000 willingness to pay.
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Base-case analysis
The base-case analysis compared the lifetime cost-effectiveness
of different shortened treatment durations against the standard
12-week treatment duration for GT1 noncirrhotic treatment-naive
patients in the United Kingdom. We calculated expected costs and
quality-adjusted life-years (QALYs) per 1000 patients using a
probabilistic analysis, with parameters sampled from predefined
distributions over 10 000 simulations in Microsoft Excel soft-
ware.36 The expected costs and QALYs were computed as an
average over the 10 000 simulations. We calculated the expected
incremental net monetary benefit (INMB) of each shortened
treatment strategy relative to 12 weeks of treatment, assuming a
willingness-to-pay (WTP) threshold of £20 000:
Expected INMB ¼ ðExpected QALYsÞ  £20 000 2ðExpected costsÞ:
We also calculated the expected cost per cure:
Cost per cure ¼ cCost½duration
pCured½duration0
where pCured is the proportion of patients cured over the treat-
ment duration. We reported the probability that any strategy was
the most cost-effective treatment strategy at different WTP
thresholds using cost-effectiveness acceptability curves.
Sensitivity analyses
We considered alternative DAA regimens currently used in the
United Kingdom as first-line treatment to assess the impact of
different drug prices and utility scores on cost-effectiveness. These
included LDV/SOF, daclatasvir plus sofosbuvir (DCV/SOF), and
elbasvir/grazoprevir (ELB/GZR). (The cost and utility
estimates used in these analyses are detailed in Appendix 3 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
018.12.011.)
We assessed the impact on cost-effectiveness of lower drug
prices. The base-case analysis used prices reported in the NICE
technology appraisals; nevertheless, reduced drug prices were
agreed by the drug manufacturers and NICE, which have not been
made publicly available. In a sensitivity analysis, we reduced drug
prices by 80% (to £7284.34 and £8965.40 per 12-week course for
first-line treatment and re-treatment, respectively). We
considered alternative discount rates in sensitivity analyses to
assess the impact of lower (1.5%) and higher (5%) discount rates oncost-effectiveness findings. This was useful to assess the
generalizability of our findings to other healthcare settings where
different discount rates are applied. Here, we assumed the same
80% reduction in drug prices.
Scenario analyses
Because of uncertainty in the cost of treatment in the United
Kingdom and elsewhere, we used a threshold analysis to investi-
gate cost-effectiveness under different drug prices. Here, we
ranged the cost from £0 to £40 000 per 12-week course for both
first-line treatment and re-treatment simultaneously.
We also used threshold analyses to investigate the impact of
different first-line cure rates on cost-effectiveness for each
shortened treatment strategy separately, assuming the same 80%
reduction in drug prices. First, we considered higher SVR rates for
the 8-week treatment, holding all else constant, because the base-
case rate of 87% was somewhat conservative; higher success rates
over 8 weeks have been reported for other regimens,37 as well as
newer DAAs.38 In this scenario, we ranged SVR12 between 86%
and 96%. After the 6-week treatment, we varied the first-line cure
rate between 40% and 85% (ie, between the SVR12 after 4 [38%]
and 8 [87%] weeks of treatment), holding all else constant. Finally,
we investigated the cost-effectiveness of the 4-week treatment at
higher cure rate thresholds, constrained at 65% (ie, constrained at
the SVR12 after 6 weeks of treatment).
Because of some uncertainty in the cure rate after re-
treatment, we conducted a threshold analysis on this parameter
also. Here, we varied the cure rate between 0% and 100% and
assumed the same thresholds for each shortened treatment
strategy. We assumed the same 80% reduction in drug prices in
this scenario also.Results
Base-Case Findings
The 8-week treatment generated lower expected lifetime costs
and fewer QALY gains compared with the 12-week treatment. The
strategy had the lowest expected lifetime cost per cure at £32607
(95% confidence interval [CI] £29288-£36 699). At a WTP
threshold of £20 000, despite the smaller QALY gains, the strategy
had the highest INMB per 1000 patients at £7737 (95% CI £3242-
£11819) because of the considerable cost savings associated with
the shortened treatment strategy (Table 2). At 56%, the strategy
had the highest probability of being the most cost-effective
Figure 2. Probability of cost-effectiveness at £20000 willingness to pay and different drug costs.
1.0
0.8
0.6
0.4
0.2
0.0
0 10,000 20,000 30,000 40,000
Pr
ob
ab
ili
ty
 m
os
t c
os
t-
eff
ec
tiv
e
Drug cost per 12-week corse, £
8 weeks
6 weeks
4 weeks
12 weeks
ECONOMIC EVALUATION 699option. The 6-week treatment produced a positive expected INMB,
although some uncertainty was observed because of imprecise
estimates on the effectiveness of shortened treatment (INMB
£1860 [95% CI 2£14517 to £15153]). The strategy had a lower
probability of being the most cost-effective at 25%. Similar un-
certainty was observed in the 4-week treatment strategy, which
produced a negative expected INMB (2£4735 [95% CI 2£24197 to
£20141]) because of higher overall lifetime costs and lower QALY
gains. The strategy had 17% probability of being the most cost-
effective.
Sensitivity Analyses Findings
Changing the drug regimen for first-line treatment did not
affect the base-case findings, except in the case of the 4-week
treatment strategy that produced a positive INMB using DCV/
SOF as first-line treatment. The main driver for this change was
the increased cost of first-line treatment, which increased the
overall cost of the 12-week treatment. In all cases, the 8- and 6-
week treatment strategies produced a positive expected INMB
(see Appendix 3 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2018.12.011). Greater uncertainty was observed
when DCV/SOF was used as first-line treatment; nevertheless, the
shortened treatment strategies had comparably higher probabili-
ties of being the most cost-effective treatment strategies
compared with the 12-week treatment (see Appendix 3 in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2018.12.
011).
Reducing drug costs by 80% introduced some uncertainty in
the results. Because of the reduced cost savings, the 8-week
treatment strategy returned a considerably smaller INMB with
some uncertainty observed (£1370 [95% CI 2£344 to £2685]).
Nevertheless, the strategy still had the highest probability (47%) of
being the most cost-effective because of lower expected lifetime
costs (Table 2; cost-effectiveness acceptability curves arepresented in Appendix 4 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2018.12.011).
The results were robust to changes in the discount rate (see
Appendix 5 in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2018.12.011). At the lower rate of 1.5%, the same un-
certainty was observed, and the 8-week treatment strategy still
had the highest probability of being the most cost-effective, at
46%. At the higher rate of 5.0%, the probability that the 8-week
treatment was the most cost-effective increased to 50% and no
uncertainty in the expected INMB was observed.Scenario Analyses Findings
Figure 2 presents the findings from the drug-cost threshold
analysis. The results are plotted using information on the proba-
bility of cost-effectiveness at £20 000 WTP. The horizontal axis
presents the different drug costs. At 0 drug costs, the 12-week
treatment was the most cost-effective option because of the
obvious QALY advantage over the shortened treatment strategies.
Nevertheless, the 8-week treatment had the highest probability of
being the most cost-effective at all drug costs above 0 because of
the available cost savings. At all prices higher than £6000 per 12-
week course, the 6-week treatment had a consistently higher
probability (.20%) than the 12-week treatment of being the most
cost-effective. The 4-week treatment had a consistently low
probability (,20%) of being the most cost-effective strategy at all
drug prices.
Figure 3 presents the findings from the first-line cure rate
threshold analysis after 8, 6, and 4 weeks of treatment, respec-
tively. The results are similarly plotted using information on the
probability of cost-effectiveness. The probability that the 8-week
treatment duration is cost-effective increases with each percent-
age increase in SVR12 (Figure 3A). At 96% SVR12, ceteris paribus,
the probability that the strategy is the most cost-effective is 60%. If
Figure 3. Probability of cost-effectiveness at £20000 willingness to pay and different first-line cure rate thresholds: (A) 8-wk treatment;
(B) 6-wk treatment; (C) 4-wk treatment.
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700 VALUE IN HEALTH JUNE 2019SVR12 after the 6-week treatment was 77% or higher, ceteris
paribus, the strategy had the highest probability of being the most
cost-effective strategy (Figure 3B). The 4-week treatment had the
lowest probability of being the most cost-effective, even when
SVR12 was as high as 65% (Figure 3C).The results from the re-treatment cure rate threshold analysis
are presented in Figure 4. At re-treatment cure rates higher than
65%, the 8-week treatment had the highest probability of being
the most cost-effective strategy. The 6- and 4-week treatments
had a higher probability of being cost-effective compared with the
Figure 4. Probability of cost-effectiveness at £20000 willingness to pay and different re-treatment cure rate thresholds.
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97.5% or higher, respectively.Discussion
Strengths and Limitations
To our knowledge, this is the first study to consider the cost-
effectiveness of short-course therapy for chronic HCV. We
compared 3 different shortened treatment durations using data
reported in the literature for a noncirrhotic treatment-naive
population. We developed a decision tree to capture treatment
outcomes and adapted a previously validated Markov model to
reflect the disease history of HCV. We assessed a number of DAA
regimens currently used in the United Kingdom and conducted
various sensitivity and scenario analyses. Our results were
generally robust to these analyses.
There are limitations to this work. The evidence on the effec-
tiveness of shortened treatment duration is limited, and often
limited to DAAs not currently approved. With the exception of
Kowdley et al11 who reported the effectiveness of 3D treatment,
which is currently recommended for use internationally, most
studies considered the effectiveness of a combination of DAA
regimens,12 or explored the effectiveness of existing DAA regimens
but with the addition of an investigational nonnucleoside or
protease inhibitor, for example.13,39,40 As a consequence, these
analyses have had little impact on policy. For instance, in the
United Kingdom, the recommended standard treatment duration
for all DAA regimens in GT1 is 12 to 16 weeks, with the exception
of LDV/SOF, which is recommended for use over 8 weeks in pa-
tients with low baseline viral load, and glecaprevir/pibrentasvir,
which is a new regimen that is licensed for use over 8 weeks.41
Although the evidence is limited, we used the data from Kowd-
ley et al11 as our baseline source for efficacy data on 12 and 8weeks of treatment and predicted the expected cure rate for this
regimen over 6- and 4-week durations using data from Sulkowski
et al.12
The evidence for the effectiveness of re-treatment is also
limited, although most studies report considerably high success
rates in GT1 noncirrhotic patients.15,17-20,42 For our analysis, we
used recent evidence from Bourliere et al20 who investigated
the effectiveness of re-treatment using the now currently rec-
ommended re-treatment regimen (SOF/VEL/VOX) over 12
weeks for a similar noncirrhotic population that failed first-line
therapy. In scenario analysis, we assessed lower re-treatment
cure rates and found that the shortened treatment strategies
were more cost-effective than the 12-week treatment, provided
SVR12 after re-treatment was 65% or higher after the 8-week
treatment, and 92.5% and 97.5% after the 6- and 4-week treat-
ment, respectively.
Although the cost of DAA treatment is high, we do not know
the actual price healthcare payers pay for these drugs. In our base-
case analysis, we assumed the prices reported in the technology
appraisals,7-9,43 which are an exaggeration of the actual prices
paid. In a threshold analysis, we varied these prices and found that
the base-case findings remained generally robust at prices lower
than £40 000 per 12-week course.
Finally, we took a UK perspective in this article. Although some
variations in monitoring costs might exist internationally, there is
little to differentiate in terms of treatment costs, patient out-
comes, and disease progression. Discount rates differ across some
settings; for instance, in Australia, Estonia, Latvia, Lithuania, and
Ireland, the applied discount rate is 5%, whereas in Canada it is
1.5%.44 We applied these rates in sensitivity analyses and found
that the results remained generally unchanged, suggesting that
our findings may be generalizable to other healthcare settings that
assume the same, or either lower or higher, discount rates. The
findings are also likely generalizable across DAA regimens, which
are generally homogeneous; DAAs have similar cure rates,
702 VALUE IN HEALTH JUNE 2019comparably high treatment costs, and uniform impact on patients’
quality of life. We did not explore strategies that might stratify
patients as suitable for shortened therapy at 4 and 6 weeks,
although such approaches are likely to improve the cost-
effectiveness of treatment.
Implications for Practice
Our findings that the 8-week (or even 6-week) shortened
treatment duration is likely to be cost-effective are important in
the context of clinical practice. Treating patients over shortened
durations in resource-constrained settings, for example, allows
scarce resources, such as staff, to be better allocated and distrib-
uted although such approaches need to be balanced against the
complexity of delivering care. The decision to treat patients,
particularly those with high loss to follow-up, such as chaotic drug
users, is also less problematic. Treating these patients over
shortened treatment durations is effective and cost-effective if a
salvage treatment can be administered. This may be useful in
settings in which there is a limited time available for treatment
(eg, prisons); nevertheless, the decision to treat patients serving
short sentences remains problematic because of loss to follow-up.
Future research should identify the potential cost-effectiveness of
shortened treatment durations in this context.
Although short-course therapy is not currently recommended,
the cost-effectiveness of this approach is clear. Shortening treat-
ment to 8 or 6 weeks using existing DAA therapies, such as 3D,
LDV/SOF, DCV/SOF, and ELB/GZR, appears cost-effective, although
some uncertainty in the 6-week treatment strategy exists. We
highlight the need for further evidence on the efficacy of 6 and 4
weeks of treatment using licensed regimens, along with evidence
on the success of re-treatment. Future research should also
identify patients for whom shortened treatment is likely to be
effective, with treatment duration optimized on the basis of
baseline viral load or resistance to DAA therapies, for example,
which has been shown to limit patients’ chance of viral eradica-
tion,45,46 particularly in those with prolonged exposure to treat-
ment previously.15Conclusions
We compared the lifetime cost-effectiveness of 3 unstratified
shortened treatment durations (8, 6, and 4 weeks) against the
standard 12-week treatment, with a re-treatment strategy
adopted for all patients who failed first-line treatment, for GT1
noncirrhotic treatment-naive patients in the United Kingdom. The
8-week treatment generates marginally fewer expected lifetime
QALYs than the 12-week treatment duration, but is the most
cost-effective option because of considerably lower expected
lifetime costs arising from lower first-line treatment costs. There is
considerable uncertainty surrounding the cost-effectiveness of 6
and 4 weeks of treatment because of limited evidence on efficacy,
although there is some indication that the 6-week treatment may
be cost-effective, whereas the 4-week treatment is likely not
cost-effective.
Provided drug costs are above 0, the 8-week treatment has the
highest probability of being the most cost-effective because of the
available cost savings versus the standard 12-week treatment. The
6-week treatment had a higher probability than the 12-week
treatment of being the most cost-effective at all drug prices
higher than £6000 per 12-week course; nevertheless, the proba-
bility was generally low at approximately 30%. The 8-week
treatment is highly cost-effective at higher first-line cure rates;
at 96% SVR12, the strategy has 60% probability of being the mostcost-effective. The 6-week treatment would be the most cost-
effective option if the first-line cure rate was 77% or higher,
whereas the 4-week treatment always had a low probability of
being the most cost-effective, even when the first-line cure rate
was as high as 65%. Shortening treatment duration is cost-
effective if the re-treatment cure rate is 65% or higher after the
8-week treatment, or 92.5% and 97.5% after the 6- and 4-week
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